

For Immediate Release

CordLife is Southeast Asia's First AABB Accredited Cord Blood Bank

CyGenics subsidiary's commitment to quality validated

6th September, 2005 – Leading cell therapy company CyGenics Limited (ASX: CYN) announced today that its umbilical cord blood banking subsidiary CordLife, had been granted the prestigious AABB accreditation, the organization formerly known as the American Association of Blood Banks. It is the first such bank in Southeast Asia to achieve this status.

This accreditation had been granted following an intensive on-site assessment by specially trained AABB assessors. During this audit, it was determined that CordLife's level of medical, technical and administrative performance met or exceeded the standards set by the AABB. Today, only 35 private and public cord blood banks around the world have achieved this standard. CordLife is the 8th private bank outside the United States and the first in the Southeast Asian region to be accredited.

AABB is an international non-profit body dedicated to developing the highest standards in blood and cord blood banking, transfusion medicine and cellular therapy. Its very strict and comprehensive standards are today considered the world standard in these fields. Its accreditation is sought after by public and commercial organizations as it demonstrates a commitment to advanced learning, continuous improvement and innovation to sustain the highest possible level of quality and safety in patient and donor care.

Parents banking with an AABB accredited bank can be assured that the best possible sample has been qualified, collected, tested, processed, and stored properly. Should the cord blood sample be needed in the future, a transplanting physician anywhere in the world will know that the sample has been collected, tested, processed and stored in a way that is consistent with enhancing the chances of a successful transplant.

"The way we qualify, collect, process, test, store, and even label our units, was very rigorously audited," said Dr Toh Keng Kiat, CordLife's Laboratory Director. "From our very first sample, we have been adhering very strictly to the AABB's high standards in everything we do. With our accreditation, that adherence has been formally recognised."

"AABB accreditation demonstrates that we are dealing with an organization committed to quality," said Professor Bob Williamson, an internationally renowned scientist and former director of the Murdoch Childrens Research Institute, the largest research institute specializing in child and adolescent health in Australia. "Any



transplant doctor anywhere in the world would be confident that a cord blood unit received from such a facility can be used effectively in a transplant at any time in the future.”

The accreditation process extended even into non-lab functions such as sales, marketing and HR. Great emphasis, for example, was put on the accuracy of the marketing material used by the company. Everything that CordLife says or does in dealing with its customers, must be supported by technical and scientific data.

“The voluntary AABB accreditation is not only necessary in today’s growing cell therapy market, but is the globally recognised standard for all operating cord blood banks. That CordLife is willing to undertake this expensive and time-intensive process, demonstrates the company’s ongoing commitment to quality,” said Steven Fang, Group CEO, CyGenics. “We are extremely pleased to have been granted this accreditation. From CordLife’s early days, the company had set for itself the goal of providing the best possible service to our customers. We have met or exceeded the AABB’s very stringent standards. Today, that commitment to quality has been validated.”

Processing of cord blood in CordLife’s AABB accredited facility in Singapore







About the AABB

Established in 1947, AABB is an international association of blood banks, including hospital and community blood centers, transfusion and cellular therapy services and individuals involved in activities related to transfusion and transplantation medicine. AABB supports high standards of medical, technical and administrative performance, scientific investigation, clinical application and education. It is dedicated to encouraging the voluntary donation of blood and other tissues and organs through education, public information and research. Approximately 1,800 institutions (community and hospital blood banks, hospital transfusion services, cell therapy, cord blood banks, and laboratories) and 8,000 individuals are members of AABB, including physicians, nurses, scientists, administrators, medical technologists, blood donor recruiters and public relations personnel. Members are located in all 50 states in the USA and 80 foreign countries.

About CordLife

CordLife is a subsidiary of CyGenics, a leading stem cell biotechnology and immunotherapy company. The first private cord blood bank to be set up in Singapore, and among the first in Asia, CordLife's start-of-the-art facility is the first in Southeast Asia to be accredited by AABB, and is the only bank to be so accredited in this region. These banking facilities comprise full processing and cryogenic storage capabilities. For further information, please visit www.cordlife.com.

About CyGenics

CyGenics is a cell therapy company focused on the development and commercialisation of adult stem cell-related products, services, applications and technologies. From its headquarters in Australia, CyGenics operates four subsidiaries: Singapore-based CordLife (tissue banking services, in particular, cord blood banking) and Cell Sciences (consumable cell culture products), and Cytomatrix (cell therapeutics and technology development) based in Boston, USA, and CytoVations (new product development) based in New Jersey, USA. CyGenics is listed on the Australian Stock Exchange, under the symbol CYN. For more information, please visit www.cygenics.com.

For more information, please contact:

Ian Brown, COO Ph: +61 (0)3 9642 5580 Mob: +61 (0)438 565 212 Email: ian.brown@cygenics.com	Rebecca Piercy Buchan Consulting Ph: +61 (0)3 9866 4722 Mob: +61 (0)422 916 422 Email: rpiercy@bcg.com.au
Steven Fang, CEO Mob: +61 (0)400 933 243 Email: steven.fang@cygenics.com	
Ronald Hee Ph: +65 9061 9098 Email: ronald.hee@cygenics.com	

